ID   KCC2A_MOUSE             Reviewed;         478 AA.
AC   P11798; Q61284; Q6ZWN4;
DT   01-OCT-1989, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   18-JUN-2025, entry version 232.
DE   RecName: Full=Calcium/calmodulin-dependent protein kinase type II subunit alpha;
DE            Short=CaM kinase II subunit alpha;
DE            Short=CaMK-II subunit alpha;
DE            EC=2.7.11.17 {ECO:0000269|PubMed:23502535};
GN   Name=Camk2a;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=ICR; TISSUE=Brain;
RX   PubMed=2543961; DOI=10.1093/nar/17.10.3992;
RA   Hanley R.M., Payne M.E., Cruzalegui F., Christenson M.A., Means A.R.;
RT   "Sequence of the cDNA for the alpha subunit of calmodulin kinase II from
RT   mouse brain.";
RL   Nucleic Acids Res. 17:3992-3992(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ALPHA KAP), SUBCELLULAR LOCATION
RP   (ISOFORM ALPHA KAP), AND TISSUE SPECIFICITY.
RC   STRAIN=BALB/cJ; TISSUE=Skeletal muscle;
RX   PubMed=8524307; DOI=10.1128/mcb.16.1.29;
RA   Bayer K.-U., Loehler J., Harbers K.;
RT   "An alternative, nonkinase product of the brain-specifically expressed
RT   Ca2+/calmodulin-dependent kinase II alpha isoform gene in skeletal
RT   muscle.";
RL   Mol. Cell. Biol. 16:29-36(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Hippocampus;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M., Davis M.J.,
RA   Wilming L.G., Aidinis V., Allen J.E., Ambesi-Impiombato A., Apweiler R.,
RA   Aturaliya R.N., Bailey T.L., Bansal M., Baxter L., Beisel K.W., Bersano T.,
RA   Bono H., Chalk A.M., Chiu K.P., Choudhary V., Christoffels A.,
RA   Clutterbuck D.R., Crowe M.L., Dalla E., Dalrymple B.P., de Bono B.,
RA   Della Gatta G., di Bernardo D., Down T., Engstrom P., Fagiolini M.,
RA   Faulkner G., Fletcher C.F., Fukushima T., Furuno M., Futaki S.,
RA   Gariboldi M., Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N., Hill D.,
RA   Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T., Jakt M.,
RA   Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H., Kitano H.,
RA   Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K., Kurochkin I.V.,
RA   Lareau L.F., Lazarevic D., Lipovich L., Liu J., Liuni S., McWilliam S.,
RA   Madan Babu M., Madera M., Marchionni L., Matsuda H., Matsuzawa S., Miki H.,
RA   Mignone F., Miyake S., Morris K., Mottagui-Tabar S., Mulder N., Nakano N.,
RA   Nakauchi H., Ng P., Nilsson R., Nishiguchi S., Nishikawa S., Nori F.,
RA   Ohara O., Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G.,
RA   Pesole G., Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z.,
RA   Ringwald M., Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B., Sperling S.,
RA   Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K., Tammoja K.,
RA   Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A., Ueda H.R.,
RA   van Nimwegen E., Verardo R., Wei C.L., Yagi K., Yamanishi H.,
RA   Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C., Grimmond S.M.,
RA   Teasdale R.D., Liu E.T., Brusic V., Quackenbush J., Wahlestedt C.,
RA   Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y., Fukuda S.,
RA   Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T., Iida J., Imamura K.,
RA   Itoh M., Kato T., Kawaji H., Kawagashira N., Kawashima T., Kojima M.,
RA   Kondo S., Konno H., Nakano K., Ninomiya N., Nishio T., Okada M., Plessy C.,
RA   Shibata K., Shiraki T., Suzuki S., Tagami M., Waki K., Watahiki A.,
RA   Okamura-Oho Y., Suzuki H., Kawai J., Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   PROTEIN SEQUENCE OF 9-21; 33-42; 135-146; 260-267; 301-311; 329-344;
RP   353-371; 397-405; 434-445 AND 470-478, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   STRAIN=OF1; TISSUE=Hippocampus;
RA   Lubec G., Sunyer B., Chen W.-Q.;
RL   Submitted (JAN-2009) to UniProtKB.
RN   [6]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=15994560; DOI=10.1126/science.1111915;
RA   Pufall M.A., Lee G.M., Nelson M.L., Kang H.S., Velyvis A., Kay L.E.,
RA   McIntosh L.P., Graves B.J.;
RT   "Variable control of Ets-1 DNA binding by multiple phosphates in an
RT   unstructured region.";
RL   Science 309:142-145(2005).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain;
RX   PubMed=16452087; DOI=10.1074/mcp.t500041-mcp200;
RA   Trinidad J.C., Specht C.G., Thalhammer A., Schoepfer R., Burlingame A.L.;
RT   "Comprehensive identification of phosphorylation sites in postsynaptic
RT   density preparations.";
RL   Mol. Cell. Proteomics 5:914-922(2006).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-13, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain;
RX   PubMed=18034455; DOI=10.1021/pr0701254;
RA   Ballif B.A., Carey G.R., Sunyaev S.R., Gygi S.P.;
RT   "Large-scale identification and evolution indexing of tyrosine
RT   phosphorylation sites from murine brain.";
RL   J. Proteome Res. 7:311-318(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-330; SER-331; SER-333;
RP   THR-336; THR-337 AND SER-404, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain, Heart, Lung, and Spleen;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and expression.";
RL   Cell 143:1174-1189(2010).
RN   [10]
RP   FUNCTION, AND MUTAGENESIS OF THR-286.
RX   PubMed=23805378; DOI=10.7554/elife.00518;
RA   Tao L., Xie Q., Ding Y.H., Li S.T., Peng S., Zhang Y.P., Tan D., Yuan Z.,
RA   Dong M.Q.;
RT   "CAMKII and Calcineurin regulate the lifespan of Caenorhabditis elegans
RT   through the FOXO transcription factor DAF-16.";
RL   Elife 2:E00518-E00518(2013).
RN   [11]
RP   FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH DAGLA, AND MUTAGENESIS OF
RP   THR-286.
RX   PubMed=23502535; DOI=10.1038/nn.3353;
RA   Shonesy B.C., Wang X., Rose K.L., Ramikie T.S., Cavener V.S., Rentz T.,
RA   Baucum A.J. II, Jalan-Sakrikar N., Mackie K., Winder D.G., Patel S.,
RA   Colbran R.J.;
RT   "CaMKII regulates diacylglycerol lipase-alpha and striatal endocannabinoid
RT   signaling.";
RL   Nat. Neurosci. 16:456-463(2013).
RN   [12]
RP   PHOSPHORYLATION AT THR-286, AND MUTAGENESIS OF GLU-183.
RX   PubMed=28130356; DOI=10.1523/jneurosci.2068-16.2017;
RA   Stephenson J.R., Wang X., Perfitt T.L., Parrish W.P., Shonesy B.C.,
RA   Marks C.R., Mortlock D.P., Nakagawa T., Sutcliffe J.S., Colbran R.J.;
RT   "Mutation Disrupts Dendritic Morphology and Synaptic Transmission, and
RT   Causes ASD-Related Behaviors.";
RL   J. Neurosci. 37:2216-2233(2017).
RN   [13]
RP   SUBCELLULAR LOCATION.
RX   PubMed=28642476; DOI=10.1038/s41598-017-04355-8;
RA   Vigil F.A., Mizuno K., Lucchesi W., Valls-Comamala V., Giese K.P.;
RT   "Prevention of long-term memory loss after retrieval by an endogenous
RT   CaMKII inhibitor.";
RL   Sci. Rep. 7:4040-4040(2017).
CC   -!- FUNCTION: Calcium/calmodulin-dependent protein kinase that functions
CC       autonomously after Ca(2+)/calmodulin-binding and autophosphorylation,
CC       and is involved in various processes, such as synaptic plasticity,
CC       neurotransmitter release and long-term potentiation (By similarity).
CC       Member of the NMDAR signaling complex in excitatory synapses, it
CC       regulates NMDAR-dependent potentiation of the AMPAR and therefore
CC       excitatory synaptic transmission (By similarity). Regulates dendritic
CC       spine development (By similarity). Also regulates the migration of
CC       developing neurons (By similarity). Phosphorylates the transcription
CC       factor FOXO3 to activate its transcriptional activity
CC       (PubMed:23805378). Phosphorylates the transcription factor ETS1 in
CC       response to calcium signaling, thereby decreasing ETS1 affinity for DNA
CC       (PubMed:15994560). In response to interferon-gamma (IFN-gamma)
CC       stimulation, catalyzes phosphorylation of STAT1, stimulating the JAK-
CC       STAT signaling pathway (By similarity). In response to interferon-beta
CC       (IFN-beta) stimulation, stimulates the JAK-STAT signaling pathway (By
CC       similarity). Acts as a negative regulator of 2-arachidonoylglycerol (2-
CC       AG)-mediated synaptic signaling via modulation of DAGLA activity
CC       (PubMed:23502535). {ECO:0000250|UniProtKB:P11275,
CC       ECO:0000250|UniProtKB:Q9UQM7, ECO:0000269|PubMed:15994560,
CC       ECO:0000269|PubMed:23502535, ECO:0000269|PubMed:23805378}.
CC   -!- FUNCTION: [Isoform Alpha KAP]: Has no kinase activity.
CC       {ECO:0000269|PubMed:8524307}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP +
CC         H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.17;
CC         Evidence={ECO:0000269|PubMed:15994560, ECO:0000269|PubMed:23502535};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] +
CC         ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA-
CC         COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.17;
CC         Evidence={ECO:0000269|PubMed:23502535};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000250|UniProtKB:Q9UQM7};
CC   -!- ACTIVITY REGULATION: Activated by Ca(2+)/calmodulin. Binding of
CC       calmodulin results in conformational change that relieves intrasteric
CC       autoinhibition and allows autophosphorylation of Thr-286 which turns
CC       the kinase in a constitutively active form and confers to the kinase a
CC       Ca(2+)-independent activity. {ECO:0000250|UniProtKB:Q9UQM7}.
CC   -!- SUBUNIT: There are 4 genes encoding calcium/calmodulin-dependent
CC       protein kinase type II chains: CAMK2A, CAMK2B, CAMK2G and CAMK2D. The
CC       corresponding proteins assemble into homo- or heteromultimeric
CC       holoenzymes composed of 12 subunits with two hexameric rings stacked
CC       one on top of the other (By similarity). Interacts with BAALC.
CC       Interacts with MPDZ. Interacts with SYN1. Interacts with CAMK2N2.
CC       Interacts with SYNGAP1. Interacts with SYNPO2 (By similarity).
CC       Interacts with SHANK3. Interacts with GRIN2B. Interacts with CACNB2.
CC       Interacts with LRRC7. Interacts with GRM5 (By similarity). Interacts
CC       with DAGLA (via C-terminal); this interaction is enhanced by
CC       autophosphorylation of CAMK2A at Thr-286 (PubMed:23502535). Interacts
CC       with CAMK2N1; this interaction requires CAMK2A activation by Ca(2+) (By
CC       similarity). {ECO:0000250|UniProtKB:P11275,
CC       ECO:0000250|UniProtKB:Q9UQM7, ECO:0000269|PubMed:23502535}.
CC   -!- INTERACTION:
CC       P11798; Q9JI91: Actn2; NbExp=3; IntAct=EBI-400384, EBI-299169;
CC       P11798; Q62108: Dlg4; NbExp=4; IntAct=EBI-400384, EBI-300895;
CC       P11798; Q01097: Grin2b; NbExp=5; IntAct=EBI-400384, EBI-400125;
CC       P11798; Q00960: Grin2b; Xeno; NbExp=4; IntAct=EBI-400384, EBI-396905;
CC       P11798; P70587: Lrrc7; Xeno; NbExp=2; IntAct=EBI-400384, EBI-7798464;
CC       P11798-2; Q9Z1R2: Bag6; NbExp=3; IntAct=EBI-400402, EBI-644645;
CC   -!- SUBCELLULAR LOCATION: [Isoform Alpha KAP]: Cytoplasm
CC       {ECO:0000305|PubMed:8524307}.
CC   -!- SUBCELLULAR LOCATION: Synapse {ECO:0000269|PubMed:28642476}.
CC       Postsynaptic density {ECO:0000250|UniProtKB:P11275}. Cell projection,
CC       dendritic spine {ECO:0000250|UniProtKB:Q9UQM7}. Cell projection,
CC       dendrite {ECO:0000250|UniProtKB:Q9UQM7}. Note=Postsynaptic lipid rafts.
CC       {ECO:0000250|UniProtKB:P11275}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Alpha CaMKII;
CC         IsoId=P11798-1; Sequence=Displayed;
CC       Name=Alpha KAP {ECO:0000303|PubMed:8524307};
CC         IsoId=P11798-2; Sequence=VSP_004767, VSP_004768, VSP_004769;
CC   -!- TISSUE SPECIFICITY: [Isoform Alpha CaMKII]: Expressed in brain.
CC       {ECO:0000269|PubMed:8524307}.
CC   -!- TISSUE SPECIFICITY: [Isoform Alpha KAP]: Expressed in skeletal muscle.
CC       {ECO:0000269|PubMed:8524307}.
CC   -!- PTM: Autophosphorylation of Thr-286 following activation by
CC       Ca(2+)/calmodulin. Phosphorylation of Thr-286 locks the kinase into an
CC       activated state. {ECO:0000269|PubMed:28130356}.
CC   -!- PTM: Palmitoylated. Probably palmitoylated by ZDHHC3 and ZDHHC7.
CC       {ECO:0000250|UniProtKB:P11275}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr
CC       protein kinase family. CaMK subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X14836; CAA32946.1; -; mRNA.
DR   EMBL; X87142; CAA60620.1; -; mRNA.
DR   EMBL; AK083245; BAC38829.1; -; mRNA.
DR   EMBL; BC031745; AAH31745.1; -; mRNA.
DR   CCDS; CCDS29276.1; -. [P11798-1]
DR   CCDS; CCDS29277.1; -. [P11798-2]
DR   PIR; JC6083; JC6083.
DR   PIR; S04365; S04365.
DR   RefSeq; NP_001273738.1; NM_001286809.1.
DR   RefSeq; NP_033922.1; NM_009792.3. [P11798-2]
DR   RefSeq; NP_803126.1; NM_177407.4. [P11798-1]
DR   PDB; 1HKX; X-ray; 2.65 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N=336-478.
DR   PDB; 4X3I; X-ray; 1.80 A; B=309-315.
DR   PDB; 6TS3; X-ray; 1.28 A; C/D=294-315.
DR   PDB; 7B55; X-ray; 1.60 A; B=1-315.
DR   PDB; 7B56; X-ray; 1.45 A; B=1-315.
DR   PDB; 7B57; X-ray; 1.95 A; B=1-315.
DR   PDBsum; 1HKX; -.
DR   PDBsum; 4X3I; -.
DR   PDBsum; 6TS3; -.
DR   PDBsum; 7B55; -.
DR   PDBsum; 7B56; -.
DR   PDBsum; 7B57; -.
DR   AlphaFoldDB; P11798; -.
DR   SMR; P11798; -.
DR   BioGRID; 198461; 44.
DR   CORUM; P11798; -.
DR   DIP; DIP-31593N; -.
DR   FunCoup; P11798; 2413.
DR   IntAct; P11798; 51.
DR   MINT; P11798; -.
DR   STRING; 10090.ENSMUSP00000099952; -.
DR   GuidetoPHARMACOLOGY; 1555; -.
DR   GlyGen; P11798; 6 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (4 sites).
DR   iPTMnet; P11798; -.
DR   MetOSite; P11798; -.
DR   PhosphoSitePlus; P11798; -.
DR   SwissPalm; P11798; -.
DR   jPOST; P11798; -.
DR   PaxDb; 10090-ENSMUSP00000099952; -.
DR   PeptideAtlas; P11798; -.
DR   ProteomicsDB; 263582; -. [P11798-1]
DR   ProteomicsDB; 263583; -. [P11798-2]
DR   Antibodypedia; 3814; 867 antibodies from 51 providers.
DR   DNASU; 12322; -.
DR   Ensembl; ENSMUST00000102888.10; ENSMUSP00000099952.4; ENSMUSG00000024617.17. [P11798-1]
DR   Ensembl; ENSMUST00000115295.9; ENSMUSP00000110950.3; ENSMUSG00000024617.17. [P11798-2]
DR   GeneID; 12322; -.
DR   KEGG; mmu:12322; -.
DR   UCSC; uc008fbg.2; mouse. [P11798-1]
DR   UCSC; uc008fbh.2; mouse. [P11798-2]
DR   AGR; MGI:88256; -.
DR   CTD; 815; -.
DR   MGI; MGI:88256; Camk2a.
DR   VEuPathDB; HostDB:ENSMUSG00000024617; -.
DR   eggNOG; KOG0033; Eukaryota.
DR   GeneTree; ENSGT00940000155150; -.
DR   HOGENOM; CLU_000288_71_0_1; -.
DR   InParanoid; P11798; -.
DR   OMA; YFENCEF; -.
DR   OrthoDB; 92711at9989; -.
DR   BRENDA; 2.7.11.17; 3474.
DR   Reactome; R-MMU-3371571; HSF1-dependent transactivation.
DR   Reactome; R-MMU-399719; Trafficking of AMPA receptors.
DR   Reactome; R-MMU-4086398; Ca2+ pathway.
DR   Reactome; R-MMU-438066; Unblocking of NMDA receptors, glutamate binding and activation.
DR   Reactome; R-MMU-5578775; Ion homeostasis.
DR   Reactome; R-MMU-5673000; RAF activation.
DR   Reactome; R-MMU-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-MMU-877300; Interferon gamma signaling.
DR   Reactome; R-MMU-936837; Ion transport by P-type ATPases.
DR   BioGRID-ORCS; 12322; 2 hits in 79 CRISPR screens.
DR   CD-CODE; CE726F99; Postsynaptic density.
DR   ChiTaRS; Camk2a; mouse.
DR   EvolutionaryTrace; P11798; -.
DR   PRO; PR:P11798; -.
DR   Proteomes; UP000000589; Chromosome 18.
DR   RNAct; P11798; protein.
DR   Bgee; ENSMUSG00000024617; Expressed in dentate gyrus of hippocampal formation granule cell and 175 other cell types or tissues.
DR   ExpressionAtlas; P11798; baseline and differential.
DR   GO; GO:0005954; C:calcium- and calmodulin-dependent protein kinase complex; ISS:UniProtKB.
DR   GO; GO:0043197; C:dendritic spine; ISS:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IDA:BHF-UCL.
DR   GO; GO:0014069; C:postsynaptic density; IDA:MGI.
DR   GO; GO:0098685; C:Schaffer collateral - CA1 synapse; IDA:SynGO.
DR   GO; GO:0045202; C:synapse; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004683; F:calcium/calmodulin-dependent protein kinase activity; IDA:CAFA.
DR   GO; GO:0005516; F:calmodulin binding; IDA:CAFA.
DR   GO; GO:0035254; F:glutamate receptor binding; IPI:MGI.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:MGI.
DR   GO; GO:0006816; P:calcium ion transport; IMP:MGI.
DR   GO; GO:0035458; P:cellular response to interferon-beta; ISS:UniProtKB.
DR   GO; GO:0048813; P:dendrite morphogenesis; IMP:MGI.
DR   GO; GO:0060996; P:dendritic spine development; ISS:UniProtKB.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IMP:MGI.
DR   GO; GO:0051346; P:negative regulation of hydrolase activity; IMP:UniProtKB.
DR   GO; GO:1990443; P:peptidyl-threonine autophosphorylation; IMP:UniProtKB.
DR   GO; GO:0051928; P:positive regulation of calcium ion transport; IMP:MGI.
DR   GO; GO:0010666; P:positive regulation of cardiac muscle cell apoptotic process; IMP:MGI.
DR   GO; GO:0046427; P:positive regulation of receptor signaling pathway via JAK-STAT; ISS:UniProtKB.
DR   GO; GO:2000124; P:regulation of endocannabinoid signaling pathway; IMP:UniProtKB.
DR   GO; GO:1902108; P:regulation of mitochondrial membrane permeability involved in apoptotic process; IMP:MGI.
DR   GO; GO:2001222; P:regulation of neuron migration; ISS:UniProtKB.
DR   GO; GO:0048168; P:regulation of neuronal synaptic plasticity; IMP:MGI.
DR   GO; GO:0046928; P:regulation of neurotransmitter secretion; IMP:MGI.
DR   GO; GO:0099148; P:regulation of synaptic vesicle docking; IDA:SynGO.
DR   GO; GO:0002931; P:response to ischemia; IMP:MGI.
DR   CDD; cd14086; STKc_CaMKII; 1.
DR   FunFam; 1.10.510.10:FF:000001; Calcium/calmodulin-dependent protein kinase type II subunit delta; 1.
DR   FunFam; 3.30.200.20:FF:000002; Calcium/calmodulin-dependent protein kinase type II subunit delta isoform 2; 1.
DR   FunFam; 3.10.450.50:FF:000001; calcium/calmodulin-dependent protein kinase type II subunit gamma isoform X1; 1.
DR   Gene3D; 3.10.450.50; -; 1.
DR   Gene3D; 6.10.140.620; -; 1.
DR   Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1.
DR   Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1.
DR   InterPro; IPR013543; Ca/CaM-dep_prot_kinase-assoc.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR032710; NTF2-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR24347; SERINE/THREONINE-PROTEIN KINASE; 1.
DR   Pfam; PF08332; CaMKII_AD; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF54427; NTF2-like; 1.
DR   SUPFAM; SSF56112; Protein kinase-like (PK-like); 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   TreeFam; TF315229; -.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Calmodulin-binding;
KW   Cell projection; Cytoplasm; Direct protein sequencing; Kinase; Lipoprotein;
KW   Magnesium; Metal-binding; Nucleotide-binding; Palmitate; Phosphoprotein;
KW   Reference proteome; Serine/threonine-protein kinase; Synapse; Transferase.
FT   CHAIN           1..478
FT                   /note="Calcium/calmodulin-dependent protein kinase type II
FT                   subunit alpha"
FT                   /id="PRO_0000086092"
FT   DOMAIN          13..271
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          290..300
FT                   /note="Calmodulin-binding"
FT   REGION          310..320
FT                   /note="Interaction with BAALC"
FT                   /evidence="ECO:0000250"
FT   REGION          314..341
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        322..331
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        135
FT                   /note="Proton acceptor"
FT   BINDING         19..27
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         42
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         13
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:18034455"
FT   MOD_RES         257
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P11275"
FT   MOD_RES         286
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:28130356"
FT   MOD_RES         330
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         331
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         333
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         336
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         337
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         404
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   VAR_SEQ         1..289
FT                   /note="Missing (in isoform Alpha KAP)"
FT                   /evidence="ECO:0000303|PubMed:8524307"
FT                   /id="VSP_004767"
FT   VAR_SEQ         290..314
FT                   /note="LKKFNARRKLKGAILTTMLATRNFS -> MLLFLTLWALVPCLVLLTLYFLS
FT                   ST (in isoform Alpha KAP)"
FT                   /evidence="ECO:0000303|PubMed:8524307"
FT                   /id="VSP_004768"
FT   VAR_SEQ         328
FT                   /note="K -> KKRKSSSSVQLM (in isoform Alpha KAP)"
FT                   /evidence="ECO:0000303|PubMed:8524307"
FT                   /id="VSP_004769"
FT   MUTAGEN         183
FT                   /note="E->V: Decreased protein abundance. Decreased
FT                   autophosphorylation. Changed subcellular localization.
FT                   Homozygous mice for that mutation are hyperactive and
FT                   display repetitive behaviors. They also display social
FT                   deficits and decreased exploratory behavior."
FT                   /evidence="ECO:0000269|PubMed:28130356"
FT   MUTAGEN         286
FT                   /note="T->A: Abolishes autophosphorylation. Loss of FOXO3
FT                   activation. Reduces association with DAGLA. Enhances DAGLA
FT                   enzymatic activity with an increase of 2-AG levels in
FT                   dorsolateral striatal tissue of knockin mice. Inhibition of
FT                   2-AG breakdown using JZL-184 decreased locomotor activity
FT                   in knockin mice."
FT                   /evidence="ECO:0000269|PubMed:23502535,
FT                   ECO:0000269|PubMed:23805378"
FT   MUTAGEN         286
FT                   /note="T->D: Phosphomimetic mutant. Enhanced FOXO3
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:23805378"
FT   CONFLICT        40
FT                   /note="A -> P (in Ref. 1; CAA32946)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        169
FT                   /note="A -> R (in Ref. 1; CAA32946)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        228
FT                   /note="G -> R (in Ref. 1; CAA32946)"
FT                   /evidence="ECO:0000305"
FT   HELIX           8..12
FT                   /evidence="ECO:0007829|PDB:7B56"
FT   STRAND          13..21
FT                   /evidence="ECO:0007829|PDB:7B56"
FT   STRAND          26..32
FT                   /evidence="ECO:0007829|PDB:7B56"
FT   TURN            33..36
FT                   /evidence="ECO:0007829|PDB:7B56"
FT   STRAND          37..45
FT                   /evidence="ECO:0007829|PDB:7B56"
FT   HELIX           51..66
FT                   /evidence="ECO:0007829|PDB:7B56"
FT   STRAND          75..81
FT                   /evidence="ECO:0007829|PDB:7B56"
FT   STRAND          84..89
FT                   /evidence="ECO:0007829|PDB:7B56"
FT   HELIX           97..104
FT                   /evidence="ECO:0007829|PDB:7B56"
FT   HELIX           109..128
FT                   /evidence="ECO:0007829|PDB:7B56"
FT   HELIX           138..140
FT                   /evidence="ECO:0007829|PDB:7B56"
FT   STRAND          141..144
FT                   /evidence="ECO:0007829|PDB:7B56"
FT   STRAND          152..154
FT                   /evidence="ECO:0007829|PDB:7B56"
FT   HELIX           177..179
FT                   /evidence="ECO:0007829|PDB:7B56"
FT   HELIX           182..185
FT                   /evidence="ECO:0007829|PDB:7B56"
FT   HELIX           193..208
FT                   /evidence="ECO:0007829|PDB:7B56"
FT   HELIX           218..226
FT                   /evidence="ECO:0007829|PDB:7B56"
FT   HELIX           236..239
FT                   /evidence="ECO:0007829|PDB:7B56"
FT   HELIX           242..251
FT                   /evidence="ECO:0007829|PDB:7B56"
FT   TURN            256..258
FT                   /evidence="ECO:0007829|PDB:7B56"
FT   HELIX           262..266
FT                   /evidence="ECO:0007829|PDB:7B56"
FT   HELIX           269..272
FT                   /evidence="ECO:0007829|PDB:7B56"
FT   HELIX           274..277
FT                   /evidence="ECO:0007829|PDB:7B56"
FT   HELIX           295..309
FT                   /evidence="ECO:0007829|PDB:6TS3"
FT   STRAND          310..313
FT                   /evidence="ECO:0007829|PDB:4X3I"
FT   TURN            338..340
FT                   /evidence="ECO:0007829|PDB:1HKX"
FT   HELIX           341..362
FT                   /evidence="ECO:0007829|PDB:1HKX"
FT   HELIX           366..372
FT                   /evidence="ECO:0007829|PDB:1HKX"
FT   STRAND          373..380
FT                   /evidence="ECO:0007829|PDB:1HKX"
FT   HELIX           382..384
FT                   /evidence="ECO:0007829|PDB:1HKX"
FT   STRAND          389..392
FT                   /evidence="ECO:0007829|PDB:1HKX"
FT   HELIX           393..400
FT                   /evidence="ECO:0007829|PDB:1HKX"
FT   HELIX           404..406
FT                   /evidence="ECO:0007829|PDB:1HKX"
FT   STRAND          410..421
FT                   /evidence="ECO:0007829|PDB:1HKX"
FT   STRAND          423..437
FT                   /evidence="ECO:0007829|PDB:1HKX"
FT   STRAND          445..458
FT                   /evidence="ECO:0007829|PDB:1HKX"
FT   STRAND          461..472
FT                   /evidence="ECO:0007829|PDB:1HKX"
SQ   SEQUENCE   478 AA;  54115 MW;  306F416CCE9B5F62 CRC64;
     MATITCTRFT EEYQLFEELG KGAFSVVRRC VKVLAGQEYA AKIINTKKLS ARDHQKLERE
     ARICRLLKHP NIVRLHDSIS EEGHHYLIFD LVTGGELFED IVAREYYSEA DASHCIQQIL
     EAVLHCHQMG VVHRDLKPEN LLLASKLKGA AVKLADFGLA IEVEGEQQAW FGFAGTPGYL
     SPEVLRKDPY GKPVDLWACG VILYILLVGY PPFWDEDQHR LYQQIKAGAY DFPSPEWDTV
     TPEAKDLINK MLTINPSKRI TAAEALKHPW ISHRSTVASC MHRQETVDCL KKFNARRKLK
     GAILTTMLAT RNFSGGKSGG NKKNDGVKES SESTNTTIED EDTKVRKQEI IKVTEQLIEA
     ISNGDFESYT KMCDPGMTAF EPEALGNLVE GLDFHRFYFE NLWSRNSKPV HTTILNPHIH
     LMGDESACIA YIRITQYLDA GGIPRTAQSE ETRVWHRRDG KWQIVHFHRS GAPSVLPH
//
